Evidence mapPaperPMID 28382439Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017

Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy.

Hui-Ling Zou, Yan Wang, Qiang Gang, Ying Zhang, Yu Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 5 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review.International journal of molecular sciences · 2021
    Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Micro (mi) RNA and Diabetic Retinopathy.Indian journal of clinical biochemistry : IJCB · 2022
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hui-Ling ZouDepartment of Endocrinology and Metabolism, Suqian People's Hospital, Nanjing Drum Tower Hospital, No. 138, South Yellow River Road, Suqian, 223800, Jiangsu Province, People's Republic of China.
Yan WangDepartment of Geriatrics, Suqian People's Hospital, Nanjing Drum Tower Hospital, Suqian, 223800, People's Republic of China.
Qiang GangDepartment of Endocrinology and Metabolism, Suqian People's Hospital, Nanjing Drum Tower Hospital, No. 138, South Yellow River Road, Suqian, 223800, Jiangsu Province, People's Republic of China.
Ying ZhangDepartment of Endocrinology and Metabolism, Suqian People's Hospital, Nanjing Drum Tower Hospital, No. 138, South Yellow River Road, Suqian, 223800, Jiangsu Province, People's Republic of China.
Yu SunDepartment of Endocrinology and Metabolism, Suqian People's Hospital, Nanjing Drum Tower Hospital, No. 138, South Yellow River Road, Suqian, 223800, Jiangsu Province, People's Republic of China. sqsunyu@126.com.
Nanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMicroRNA-93 (miR-93) usually acts as a promoter of tumor progression in several human carcinomas. It has been found distinctly high in eyes with proliferative diabetic retinopathy (DR). The present study aims to investigate the role of plasma miR-93 in the progression of type 2 diabetic retinopathy (T2DR).

methodsOur study subjects were made up of 140 type 2 diabetes mellitus (T2DM) patients who were assigned into DR (DR patients, n = 75), NDR (non-DR patients, n = 65), and control (healthy individuals, n = 127) groups. Levels of fasting blood glucose (FBG), fasting plasma glucose (FPG), triglyceride (TG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), blood urea nitrogen (BUN), creatinine (Cr), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and fasting insulin (FIsn) were detected by automatic biochemical analyzer. Enzyme-linked immunosorbent assay (ELISA) was performed for the levels of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF), qRT-PCR for the miR-93 expression in plasma, and mRNA expressions of IL-1, IL-6, TNF-α and VEGF; receiver operating characteristic (ROC) curve for the diagnostic performance of miR-93 to T2DR, Pearson correlation analysis for correlation analysis between miR-93 and other indexes detected before and multivariate logistic regression analyses for the risk factors for T2DR.

resultsThe DR and NDR groups exhibited elevated course of disease, and decreased levels of FBG, FPG, TG, HbA1c, TC, BUN, Cr, HDL-C, FIsn, IL-1, IL-6, TNF-α and VEGF but declined LDL-C level as compared to the control group. The course of disease was longer and the levels of FBG, FPG, HbA1c, IL1, IL6 and VEGF were higher in the DR group than those in the NDR group (all P < 0.05). The miR-93 expression and RNA expressions of IL-1, IL-6, TNF-α and VEGF were higher in the DR group than those in the NDR group (P < 0.05). The best cutoff for miR-93 to assess T2DR was 1.31, with a Youden index of 0.63, sensitivity of 73.33%, specificity of 89.24%, and area under the curve (AUC) of 0.866. Pearson correlation analysis indicated that miR-93 expression was positively associated with course of disease, the levels of FPG, HbA1c, TNF-α and VEGF. T2DM patients with longer disease course, higher levels of FBG, HbA1c, VEGF and miR-93 expression were risk factors for developing DR.

conclusionOur study demonstrates that plasma miR-93 is associated with the progression of T2DR and it can sever as a diagnostic marker for T2DR.

Indexed as

AdultAgedBiomarkersCytokinesDiabetes Mellitus, Type 2Diabetic RetinopathyDisease ProgressionEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansMaleMicroRNAsMiddle AgedRetrospective StudiesRisk FactorsBiomarkersCytokinesMicroRNAsMIRN93 microRNA, humanDiagnosisMicroRNA-93SensitivitySpecificityType 2 diabetes mellitusType 2 diabetic retinopathy

Identifiers

PMID28382439
OpenAlexW2605015833

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.